on day 35. When patients whose specimens tested positive for CMV by shell vial culture were treated with ganciclovir prophylactically, it prevented the development of CMV-IP From 1992 to 1995, 105 patients received PBSCT in our hospitals and we observed no incidence of CMV-pneufrom asymptomatic CMV infection. There are, however, few reports of the development to clinical CMV infection in monia. To clarify whether activation of CMV occurs in these patients, shell vial cultures, CMV antigenemia and patients receiving peripheral blood stem cell transplantation (PBSCT). From 1992 to 1995, 105 patients with leukemia, lymphoma every 1 to 2 weeks after transplantation to determine or solid tumors of advanced stage received PBSCT in our whether and when CMV was activated. Two patients hospitals. Seventeen patients were monitored for CMV actitested positive transiently by DNA-PCR but negative vation by three viral detection methods on day 35, and six throughout by both antigenemia and RT-PCR. These patients were monitored every 1 to 2 weeks. Details of 17 results suggest that the risk of CMV infection is low patients are given in Table 1 . For prophylaxis of CMV because the incidence of CMV activation in patients infection, all patients received irradiated blood products receiving PBSCT is low.
CMV interstitial pneumonia (IP) is a significant complication after allogenic BMT (alloBMT). The incidence of Samples CMV-IP was about 20% and the mortality rate about 80% over a 10-year period. [1] [2] [3] Prevention and treatment of Bronchoalveolar lavage (BAL) samples, peripheral blood CMV-IP is an important factor in improving the prognosis leukocyte (polymorphonuclear cells (PMNC) and monoof alloBMT patients. Recently, combined therapy with gannuclear cells (MNC)) samples and urine samples were ciclovir and anti-CMV hyperimmune globulin in the early taken from the patients on day 35 after transplantation. In stages of CMV-IP has been shown to improve survival, and addition, six of the patients were evaluated for the presence the mortality rate of such patients could be reduced to 10-of CMV antigen and DNA in PBLC using antigenemia and 20%. [4] [5] [6] [7] To further reduce the mortality rate, it is necessary PCR methods every 1 to 2 weeks after transplantation. The to prevent the development to CMV-IP from asymptomatic BAL fluid was centrifuged and divided into supernatant CMV infection. 5, 6 Schmidt et al 8 evaluated 104 patients (BALF) and pellet-containing BAL cells (BALC). BALF who had received alloBMT and from whom BAL was taken and BALC were prepared for CMV testing with shell vial culture and PCR methods. lated from EDTA-treated blood using 5% dextran solution, and an equal amount of MNC was isolated by density cen-PCR methods trifugation using Lymphoprep (Nycomed Pharma AS, Oslo, Norway). 25 l (5 × 10 4 cells) of each sample were fixed A nested PCR method for detection of CMV viral DNA and onto microscopy slides for antigenemia assay. BALF, RNA was developed. Two sets of oligonucleotide primers BALC, PMNC and MNC were also prepared for testing complimentary to sequences of the major immediate-early with shell vial culture and PCR methods to determine the gene of human CMV (AD169), were synthesized and used presence of CMV. Each urine sample (2 ml) was diluted in this study. 14 All the DNA was extracted from samples with a maintenance medium (Eagle's minimal essential using IsoQuick (OPCA Research, WA, USA). The medium to which 2% fetal bovine serum, penicillin, strepextracted DNA (3 l) was amplified in a 50 l reaction tomycin, and NH 4 CO 3 were added) and centrifuged. The (3 l of the first primer pair (5′-GAGTCCTCTGCCAsupernatant was examined by the CMV shell vial culture AGAGAAA-3′, 5′-GAGTTCTGCCAGGACATCTTT-3′), method. The original urine samples were also tested for 25 mm/l MgCl 2 , 8 mm/l dNTP, 10 × PCR buffer, and CMV-DNA and mRNA using the PCR method.
0.25 l of Taq DNA Polymerase). Thirty cycles were performed in a thermal cycler (Perkin Elmer, Norwalk, CT, USA) with the following cycle characteristics: denaturation for 1 min at 93°C, re-anealing for 1 min at 55°C, and exten-CMV antigenemia assay sion for 1 min at 72°C. A final extension step of 5 min at 72°C was used for the last cycle. The second PCR was CMV antigenemia assay was performed with a commerperformed as above, using the second primer pair (5′-cially available kit (CMV-vue Kit, Incstar, Minnesota, GAGAAAGATGGACCTGATAAT-3′, 5′-CTCGGGGTT-USA).
10 PMNC and MNC specimens containing 5 × 10 4 CTCGTTGCAA-3′) and the first PCR product. The nested cells were placed in the wells of microscopy slides PCR product was run on 3% agarose gel containing ethid-(specially coated to facilitate cell adherence). After incuium bromide, and photographed under UV light. DNA-PCR bation for 15 min at room temperature, the slides were fixed detected 10 target molecules of CMV-DNA. The RNA was in acetone for 10 min (twice), air dried, soaked in a solution extracted from samples using Isogen LS (Nippon Gene, that inhibits endogenous peroxidase, incubated for 45 min Toyama, Japan). After RNA extraction, cDNA was syntheat 37°C in a moist chamber with a mixture of two murine sized using 3 l of extracted RNA, RT, RNase inhibitor, monoclonal antibodies 11 directed against the CMV protein Randam Hexamer, dNTP, MgCl 2 and 10 × PCR buffer for pp65, 10,12,13 and stained with a horseradish peroxidase-con-30 min at 42°C. Ten microliters of this cDNA product was jugated anti-mouse immunoglobulin G antibody. The slides used for the subsequent nested PCR amplification in the were then observed under a light microscope for the pressame way as the DNA product. Each PCR experiment with ence of red-brown nuclear or perinuclear staining of CMVclinical materials included human diploid fibroblasts infected cells. Each slide included a well with fibroblasts (MRC-5) infected with the laboratory strain AD169, as infected with the CMV strain AD-169 (positive control) positive controls. Uninfected MRC-5 and PBS containing and a well with uninfected human diploid fibroblasts (negative control). 10, 11 no DNA, were included as negative controls.
Shell vial culture
leukocyte samples taken from patients by the shell vial culture method, although CMV was detected in the urine Aliquots (0.2 ml) of PMNC suspensions and 0.2 ml of specimen of case 4. PMNC and MNC samples were also phosphate buffer saline were injected into shell vials conexamined for CMV antigen using anti-CMV monoclonal taining coverslips covered with monolayers of MRC-5. 15 antibody. Positive cells which have red-brown-stained After centrifugation at 700 g for 40 min at room temperanuclei were not observed in any of these specimens. BALF, ture, culture medium (2 ml) was added to each vial. Shell BALC, PMNC, MNC and urine samples taken on day 35 vials were then incubated at 37°C in a 5% CO 2 atmosphere were examined for CMV-DNA using the DNA-PCR for 16 h and 48 h.
10, 16 After removal of the culture medium, method. In total, 74 specimens from 17 patients were examshell vials were fixed in acetone for 10 min at room temined and positive results were observed in nine specimens perature, stained with a direct immunofluorescence assay from six patients. Four of 17 patients had positive PMNC using a combination of murine monoclonal antibodies results and two of 17 patients had positive MNC results. against immediate-early antigen and early antigen of CMV One of 14 patients had positive BALF results, none of 14 (CMV Micro-Trak test; Syva Co., San Jose, CA, USA), patients had positive BALC results and two of 14 patients and observed under a fluorescence microscope for the typihad positive urine results. The nine specimens which tested cal apple-green fluorescent nuclear staining of CMVpositive with the DNA-PCR method were also examined infected cells.
for replication of CMV using the RT-PCR method. The results of these nine specimens, from six patients, were all negative.
Statistical analysis
Urine and leukocyte (PMNC and MNC) specimens from Statistical analysis to compare the incidence of CMV infecsix patients who received PBSCT were examined every 1 tion or activation was done by using the 2 test. to 2 weeks for CMV antigen and DNA using antigenemia and PCR methods ( Table 3) . None of the specimens tested positive by the antigenemia method but two of six patients Results had positive CMV-DNA transiently in the period examined when tested by the DNA-PCR method. Specimens that None of our 105 patients who received PBSCT showed any tested positive with the DNA-PCR method were also tested symptoms caused by CMV infection ( Table 2) . Out of those with the RT-PCR method. Replication of CMV was not patients, 17 patients were monitored for CMV activation. detected in any of these samples. CMV-IgM did not increase in any of the patients. Their serum level of CMV-IgG was maintained at a high level by prophylactic administration of CMV hyperimmune Discussion globulin at a dose of 200 mg/kg. Because of the poor condition of cases 3, 7 and 10, with advanced stages of heart failure or progressive disease, samples of BAL were not AlloBMT is therapeutic for aplastic anemia, chronic myeloid leukemia, acute leukemia and congenital immune taken. No inclusion bodies were detected in any of the BAL specimens. 17 CMV was not detected in any of the BAL or deficiency. CMV-IP can be a major complication after alloBMT. [1] [2] [3] The lack of HLA-identical marrow donors lim-PBSCT and from six selected patients every 1 to 2 weeks after PBSCT. CMV was not detected in any of the leukoits wider application of alloBMT for malignancies and that leads to the wide use of PBSCT in the treatment of patients cyte samples by the shell vial culture method. Van der Bij et al 11 first described antigenemia assay as a method of with these malignancies. Although there have been few reports of the occurrence of CMV pneumonia in PBSCT detecting the presence of CMV antigens in peripheral blood leukocytes (PBL) during active CMV infection. This assay patients, intensive cytoreductive therapy has been proposed as an explanation for the development of CMV-IP due to can provide a valuable marker for CMV infection in transplant recipients. Antigenemia assay showed positive results its immunosuppressive effects. 1, 17 As there have been no studies on the activation and infection of CMV in PBSCT about 1 week before onset of symptomatic CMV infection, but these decreased or disappeared during clinical recovpatients, this study aimed to investigate the occurrence and significance of CMV infections in patients who received ery. 12 CMV antigen detection had a sensitivity of 85-100% for CMV activation and 95-100% for CMV disease.
12
PBSCT.
Schmidt et al 8 conducted a controlled trial in 104 When tested by antigenemia assay, all blood samples had negative results. The DNA-PCR method can detect molecupatients who had no evidence of respiratory disease after receiving alloBMT. As the onset of CMV pneumonia usular in vitro amplification of specific target sequences by using oligonucleotide primers. PCR-positivity may precede ally occurs within 2-3 months after BMT, BAL specimens were taken on day 35 and tested by the shell vial culture antigenemia by as much as 1 week, but may remain for another few weeks or months after clinical recovery. 12, 19 method. Forty of these patients tested positive. We treated PBSCT patients with CMV prophylactic regimens in the PCR detection had a sensitivity of 91-100% for CMV activation and 95-100% for CMV disease. 12, 18 Of the 74 same way as alloBMT patients, and took BAL samples from 14 patients on day 35 after PBSCT. 3, 8, 17 Although the samples, nine specimens from six patients revealed positive DNA-PCR results. The high sensitivity of the PCR method presence of CMV in shell vial cultures of BAL is significantly associated with the development of CMV pneuhowever, raised the question as to whether positive PCR signals might be obtained during vial latency, which would monia, 8, [16] [17] [18] none of this study's patients had positive results for their specimens.
greatly limit the value of PCR for diagnosing active CMV infection. To determine whether a positive PCR result Viruria often occurs in healthy individuals, thus urine is less suitable for diagnosis of CMV activation. 6, 8 As CMV arises from the presence of a latent or replicating virus, a sensitive and reliable method for measuring specific vial viremia occurs during the acute phase of infection, it is considered a marker of CMV infection. 6 We anticipated mRNA is needed. 14 We used RT-PCR methods to detect CMV-mRNA in specimens which were CMV-DNA posithat it may be possible to increase the accuracy of early diagnosis of CMV activation by the use of other virus tive. The results were all negative. Therefore, our study suggests that a positive DNA-PCR result might not be assodetection methods such as antigenemia assay and the PCR method in addition to the shell vial culture method. We ciated with active CMV replication. PBSCT is lower than the risk associated with alloBMT. 
